Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report.
- DOI
- 10.1016/j.jtocrr.2025.100807
- Published
- 2025 Jun
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2025.100807,
title = {Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report.},
author = {Singh A and Sridhar A and Poddar A and Dimou A and Parikh K and Shanshal M and Schwecke A and Moffett N and Patel MR and Mansfield AS and Leventakos K},
year = {2025},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2025.100807},
url = {https://doi.org/10.1016/j.jtocrr.2025.100807}
}RIS
TY - JOUR TI - Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report. AU - Singh A AU - Sridhar A AU - Poddar A AU - Dimou A AU - Parikh K AU - Shanshal M AU - Schwecke A AU - Moffett N AU - Patel MR AU - Mansfield AS AU - Leventakos K PY - 2025 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2025.100807 UR - https://doi.org/10.1016/j.jtocrr.2025.100807 ER -
APA
A, S., A, S., A, P., A, D., K, P., M, S., A, S., N, M., MR, P., AS, M., & K, L. (2025). Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2025.100807
Source records
- pubmed · retrieved 2026-09-26T10:07:59.356Z